Side-by-side · Research reference

HCGvsLivagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED12/52 cited

BAnimal-StrongHUMAN-REVIEWED20/32 cited

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

01Mechanism of Action

Parameter

HCG

Livagen

Primary target

LH receptors on testicular Leydig cellsSchröder-Lange 2025

Hepatocyte protein synthesis machineryBrodskiĭ 2001

Pathway

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Downstream effect

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Feedback intact?

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

—

Origin

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Antibody development

Rare with recombinant; possible with urinary-derived formulations

—

02Dosage Protocols

Parameter

HCG

Livagen

Hypogonadotropic hypogonadism (monotherapy)

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

—

Combined therapy (hCG + FSH)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

—

Triple therapy (experimental)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

—

Cryptorchidism (pediatric)

500–4,000 IU IM 2–3×/week for 3–6 weeks

—

Evidence basis

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Duration to sperm appearance

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

—

Route

Intramuscular or subcutaneousKonsam 2026

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

Monitoring

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

—

Animal dose (oral)

—

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

Duration (experimental)

—

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

Human data

—

None in provided literature

04Side Effects & Safety

Parameter

HCG

Livagen

Injection site reaction

Pain, erythema (mild, transient)

—

Gynecomastia

Aromatization of elevated testosterone to estradiol; dose-dependent

—

Testicular discomfort / Edema

Rapid testicular growth in hypogonadal males; usually self-limiting

—

Polycythemia

Elevated hematocrit from supraphysiological testosterone; monitor CBC

—

Mood / Libido changes

Variable; usually positive with normalization of testosterone

—

Acne / Oily skin

Androgen-mediated; dose-dependent

—

Prostate concerns

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

—

Antibody formation

Rare with recombinant; possible with urinary-derived

—

Reported adverse effects

—

None documented in animal studies

Human safety data

—

No human trials in provided literature

Peptide hydrolysis

—

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

Absolute Contraindications

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

Livagen

—

Relative Contraindications

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

Livagen

—

05Administration Protocol

Parameter

HCG

Livagen

1. Reconstitution (if lyophilized)

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

2. Injection site

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

3. Timing

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

—

5. Needle selection

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).

—